The FDA has approved VIZZ, a revolutionary once-daily eye drop that treats age-related blurry near vision without affecting distance vision.
WASHINGTON, D.C.: The US Food and Drug Administration (FDA) has approved VIZZ (aceclidine ophthalmic solution), the first breakthrough treatment for presbyopia in decades. This new prescription eye drop could help millions say goodbye to reading glasses, offering clearer near vision with a simple daily routine.
VIZZ works by creating a “pinhole effect” that sharpens focus, reducing pupil size to under 2mm without blurring distance vision. Within 30 minutes of application, the drops take effect and last for up to 10 hours.
Unlike earlier presbyopia treatments such as Vuity, which sometimes caused side effects like brow heaviness or blurred distance vision, VIZZ selectively targets the iris sphincter muscle, avoiding unnecessary strain on the eye’s ciliary muscles.
Eef Schimmelpennink, CEO of LENZ Therapeutics, the company behind VIZZ, said: “This represents a transformative improvement in available treatment options for the 128 million adults living with blurry near vision in the United States.”
The approval comes after over 30,000 treatment days in Phase 3 clinical trials, which confirmed both safety and effectiveness. Eye specialist Dr. Marc Bloomenstein described the treatment as “a disruptive paradigm shift” that could quickly become the new standard of care.
For the millions of adults over 40 struggling with presbyopia, VIZZ offers a convenient alternative to reading glasses — just one drop in the morning for clear vision throughout the day.
